Syndax Pharmaceuticals, Inc. Payments of Debt Issuance Costs
Syndax Pharmaceuticals, Inc. (SNDX) reported Payments of Debt Issuance Costs of $6.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2015 was $1.25M, a 21.89% decline from fiscal 2014.
- Syndax Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2014 was $1.59M.
| Period end | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|
| 2026-06-30 | $6.15M 10-Q · filed 2026-08-04 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | |
| 2015-12-31 | $1.25M 10-K · filed 2018-03-08 | |
| 2014-12-31 | $1.59M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |